What is Mt Sinai's ranking in prostate cancer care?

Mount Sinai's Ranking in Prostate Cancer Care

Based on the available evidence, there is no specific ranking information for Mount Sinai in prostate cancer care in the provided materials. The evidence does not contain national or international ranking data for Mount Sinai Hospital's prostate cancer program.

Mount Sinai's Prostate Cancer Treatment Experience

• Mount Sinai Medical Center has documented 20 years of experience in treating prostate cancer with brachytherapy, with data on 2,495 patients showing strong outcomes 1
• Their 12-year actuarial freedom from biochemical failure was 83% across all risk groups (90% for low risk, 84% for intermediate risk, and 64% for high risk patients) 1
• Mount Sinai's treatment algorithm for prostate cancer has demonstrated 95% freedom from distant metastasis and 95% prostate cancer-specific survival at 12 years 1
• Their approach preserves potency in 61% of patients and improves urinary symptoms in 35% of patients 1

Mount Sinai's Research Contributions

• Mount Sinai has developed a comprehensive Prebiopsy Risk Calculator (MSP-RC) that combines PSA, imaging, and clinical data to predict the risk of prostate cancer 2
• This risk calculator has been validated with advanced neural networking, showing high accuracy with area under the curve of 0.90 for any prostate cancer and 0.92 for clinically significant prostate cancer 2
• The calculator was also validated against a multi-institutional European cohort and the European Randomized Study of Screening for Prostate Cancer Risk Calculator 2
• This tool is available online as a free web-based resource to aid clinicians in patient counseling and treatment decision-making 2

General Prostate Cancer Management Context

• Prostate cancer is the most common nonskin cancer in men in the US, with an estimated 299,010 new cases and 35,250 deaths in 2024 3
• Management approaches include active surveillance, radical prostatectomy, radiation therapy, and androgen deprivation therapy, depending on risk stratification 4
• The National Comprehensive Cancer Network recommends risk stratification for prostate cancer management, with options varying based on disease stage, patient age, and life expectancy 4
• Treatment decisions should consider potential side effects, with radical prostatectomy associated with erectile dysfunction (up to 80% of patients) and urinary incontinence (up to 49% of patients) 5

Treatment Approach at Mount Sinai

• Mount Sinai has developed a specific algorithm for treating localized prostate cancer with brachytherapy, either alone or in combination with external beam radiotherapy 1
• Their approach includes risk stratification and appropriate use of adjuvant androgen deprivation therapy based on risk group 1
• Significant associations were found between cancer control and risk group, total biologically effective dose, and androgen deprivation therapy in their patient cohort 1
• Their 12-year actuarial freedom from urinary retention events was 90% and from severe rectal bleeding was 93%, demonstrating relatively low morbidity 1

While Mount Sinai has demonstrated strong outcomes in prostate cancer treatment and has contributed to research in the field, the provided evidence does not include specific national or international rankings for their prostate cancer program.